Alkermes plc.

Listed Company

ALKSCIK 0001520262NasdaqLarge AcceleratedPharmaceutical PreparationsIEFY ends Dec 31

Period

FY 2025

Revenue

$1.48B

Net Income

$241.66M

Total Assets

$2.49B

Equity

$1.82B

Shares Out

166.68M

Op. Cash Flow

$520.75M

ALKS$52.71+79.39% · past yearDBEQ Basic

Daily closing prices

Business

Alkermes plc is a global biopharmaceutical company developing innovative medicines in neuroscience for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and narcolepsy. Its proprietary commercial products include ARISTADA, LYBALVI, VIVITROL, and LUMRYZ, marketed primarily in the U.S. through its own sales force. The company also receives royalties and manufacturing revenues from third-party licensees commercializing products incorporating its proprietary technologies, including long-acting injectables marketed by Janssen and VUMERITY by Biogen. Alkermes manufactures most proprietary products at its Ohio facility and maintains R&D and corporate operations in Massachusetts and Ireland.

Summary from 10-K filed 2026-02-25

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	1,476	1,558	1,663	1,112	1,174
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)	196	245	253	218	197
Research and development	324	245	271	273	291
Selling, general and administrative	702	645	690	591	550
Amortization of acquired intangible assets	—	1	36	36	38
Total expenses	1,222	1,137	1,249	1,118	1,076
OPERATING INCOME FROM CONTINUING OPERATIONS	254	421	414	−6	98
Interest income	45	42	31	8	2
Interest expense	−12	−23	−23	−13	—
Other income (expense), net	4	3	−425,000	2	219,000
Total other income, net	37	23	7	−25	−10
INCOME BEFORE INCOME TAXES	291	444	422	−31	88
INCOME TAX PROVISION (BENEFIT)	50	72	−98	2	11
NET INCOME FROM CONTINUING OPERATIONS	242	372	519	−33	76
LOSS FROM DISCONTINUED OPERATIONS, NET OF TAX	—	−5	−163	−125	−125
NET INCOME	242	367	356	−158	−48
Earnings per ordinary share from continuing operations - basic	1.47	2.25	3.12	−0.2	0.47
Loss per ordinary share from discontinued operations - basic	—	−0.03	−0.98	−0.76	−0.77
Earnings per ordinary share - basic	1.47	2.22	2.14	−0.97	−0.3
Earnings per ordinary share from continuing operations - diluted	1.43	2.2	3.06	−0.2	0.46
Loss per ordinary share from discontinued operations - diluted	—	−0.03	−0.96	−0.76	−0.76
Earnings per ordinary share - diluted	1.43	2.17	2.1	−0.97	−0.29
Basic	165	165	166	164	161
Diluted	169	169	170	164	165
Holding (loss) gain, net of a tax (benefit) provision of $(55), $292, and $1,195, respectively	−133,000	1	8	−7	−2
COMPREHENSIVE INCOME	242	368	364	−165	−51

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	389	291	457	292	338
Restricted cash	731	—	—	—	—
Investmentsshort-term	200	461	316	316	199
Receivables, net	334	385	332	288	313
Inventory	197	183	186	181	150
Prepaid expenses and other current assets	79	91	98	41	49
Contract assets	0	5	706,000	9	13
Total current assets	1,929	1,415	1,486	1,130	1,062
PROPERTY, PLANT AND EQUIPMENT, NET	222	228	227	223	341
INVESTMENTSLONG-TERM	145,000	73	40	132	229
RIGHT-OF-USE ASSETS	77	84	91	98	116
INTANGIBLE ASSETS, NET AND GOODWILL	84	84	85	—	—
DEFERRED TAX ASSETS	126	155	196	115	82
OTHER ASSETS	49	17	12	15	27
TOTAL ASSETS	2,487	2,056	2,136	1,964	2,024
Accounts payable and accrued expenses	290	185	241	220	208
Accrued sales discounts, allowances and reserves	247	272	264	252	237
Operating lease liabilitiesshort-term	7	6	6	10	16
Contract liabilitiesshort-term	0	1	3	7	6
Total current liabilities	543	465	520	498	471
OPERATING LEASE LIABILITIESLONG-TERM	63	69	76	76	104
OTHER LONG-TERM LIABILITIES	61	56	50	42	44
Total liabilities	668	591	934	920	912
COMMITMENTS AND CONTINGENT LIABILITIES (Note 19)	—	—	—	—	—
Preferred shares, par value, $0.01 per share; 50,000,000 shares authorized; and zero issued and outstanding at December 31, 2025 and 2024	—	—	—	—	—
Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 181,011,166 and 176,670,785 shares issued; and 165,607,028 and 162,176,994 shares outstanding at December 31, 2025 and 2024, respectively	2	2	2	2	2
Treasury shares, at cost (15,404,138 and 14,493,791 shares at December 31, 2025 and 2024, respectively)	−450	−419	−189	−161	−143
Additional paid-in capital	3,005	2,861	2,737	2,913	2,798
Accumulated other comprehensive loss	−2	−2	−3	−11	−4
Accumulated deficit	−735	−976	−1,344	−1,699	−1,541
Total shareholders equity	1,819	1,465	1,203	1,044	1,113
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	2,487	2,056	2,136	1,964	2,024

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net income	242	367	356	−158	−48
Depreciation and amortization	27	29	75	78	79
Share-based compensation expense	99	97	101	94	88
Deferred income taxes	29	41	−100	—	—
Other non-cash charges	5	5	6	6	3
Receivables	51	−52	−45	25	−38
Contract assets	5	−4	8	4	6
Inventory	−14	3	−3	−31	−25
Prepaid expenses and other assets	852,000	2	−35	−5	11
Right-of-use assets	8	7	15	17	17
Accounts payable and accrued expenses	101	−58	23	16	12
Accrued sales discounts, allowances and reserves	−25	9	12	15	18
Contract liabilities	−1	−4	−6	−7	−6
Operating lease liabilities	−10	−10	−16	−33	−17
Other long-term liabilities	5	8	9	13	−4
Cash flows provided by operating activities	521	439	401	21	102
Additions of property, plant and equipment	−40	−33	−48	−38	−28
Proceeds from the sale of property, plant and equipment	1	461,000	354,000	—	287,000
Return of Fountain Healthcare Partners II, L.P. investment	—	43,000	—	485,000	—
Proceeds from the sale of the Athlone Facility	2	98	—	—	—
Purchases of investments	−364	−487	−254	−310	−340
Sales and maturities of investments	697	310	356	282	295
Cash flows provided by (used in) investing activities	295	−111	53	−65	−66
Cash transferred to Mural Oncology plc at separation	—	—	−275	—	—
Proceeds from the issuance of ordinary shares under share-based compensation arrangements	43	28	17	20	25
Employee taxes paid related to net share settlement of equity awards	−31	−30	−28	−18	−17
Payment for the repurchase of ordinary shares	—	−200	—	—	—
Prepayment of long-term debt	—	−290	—	—	—
Principal payments of long-term debt	—	−2	−3	−3	−2
Cash flows provided by (used in) financing activities	12	−494	−290	−2	29
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	829	−166	165	−45	65
Cash paid for interest	—	23	23	14	7
Cash paid for taxes	5	3	44	21	2
Purchased capital expenditures included in accounts payable and accrued expenses	3	2	3	3	6

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Alkermes plc.'s CIK number?

Alkermes plc.'s SEC CIK number is 0001520262 (1520262). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Alkermes plc.'s SEC filings?

All of Alkermes plc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Alkermes plc. last report earnings?

Alkermes plc. (ALKS) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-205008). This is Alkermes plc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Alkermes plc.'s most recent earnings 8-K?

Alkermes plc.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001193125-26-205008. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Alkermes plc.'s latest earnings 8-K →
Look up any company's CIK number →